We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Astellas Pharma and BioFocus Sign Target Discovery Agreement
News

Astellas Pharma and BioFocus Sign Target Discovery Agreement

Astellas Pharma and BioFocus Sign Target Discovery Agreement
News

Astellas Pharma and BioFocus Sign Target Discovery Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Astellas Pharma and BioFocus Sign Target Discovery Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioFocus has announced that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders.

Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.

“We are delighted to support Astellas Pharma in its research” said Dr Chris Newton, SVP Galapagos Services and Managing Director BioFocus. “Our target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technology”.
Advertisement